REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Jun 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-06-12

Reporting Person: BROWN MICHAEL S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-12	Common Stock	M	2000	$177.82	Acquired	2000	Direct
2017-06-12	Common Stock	S	100	$472.04	Disposed	1900	Direct
2017-06-12	Common Stock	S	100	$477.05	Disposed	1800	Direct
2017-06-12	Common Stock	S	94	$469.02	Disposed	1706	Direct
2017-06-12	Common Stock	S	200	$473.37	Disposed	1506	Direct
2017-06-12	Common Stock	S	900	$474.37	Disposed	606	Direct
2017-06-12	Common Stock	S	606	$475.72	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-12	Non-Qualified Stock Option (right to buy)	$177.82	M	2000	Disposed	2023-01-02	Common Stock (2000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	17349	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 94 shares of Company stock on June 12, 2017 at prices ranging from $469.02 to $469.05. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price.

F3: Represents volume-weighted average price of sales of 200 shares of Company stock on June 12, 2017 at prices ranging from $473.36 to $473.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price.

F4: Represents volume-weighted average price of sales of 900 shares of Company stock on June 12, 2017 at prices ranging from $474.01 to $474.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price.

F5: Represents volume-weighted average price of sales of 606 shares of Company stock on June 12, 2017 at prices ranging from $475.65 to $475.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2017 at each separate price.

F6: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.